Back
Exelixis

Exelixis

EXEL

Loading Stocks

$22.20

$0.49 (2.26%)

1D

1W

3M

1Y

5Y

ALL

Overview

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Open

$21.88

Prior close

$21.73

Today's high

$22.23

Today's low

$21.84

52 Week high

$24.34

52 Week low

$18.64
News
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Newsfeed image icon
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Newsfeed image icon
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Newsfeed image icon
View disclosures

Start Your Investing Journey At MoneyLion

Access fully managed portfolios to help you invest towards your future, without the heavy lifting.

Market Data

Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.